190.44 USD
-1.25 (-0.65%)
At close: Feb 6, 2026
190.44 USD
0 (0%)
After Hours: 2/6/2026, 8:00:02 PM
We assign a fundamental rating of 6 out of 10 to LGND. LGND was compared to 191 industry peers in the Pharmaceuticals industry. While LGND belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. LGND is growing strongly while it is still valued neutral. This is a good combination! These ratings could make LGND a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
- LGND had positive earnings in the past year.
- In the past year LGND had a positive cash flow from operations.
- In multiple years LGND reported negative net income over the last 5 years.
- LGND had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- LGND has a Return On Assets of 3.29%. This is amongst the best in the industry. LGND outperforms 82.72% of its industry peers.
- With an excellent Return On Equity value of 5.11%, LGND belongs to the best of the industry, outperforming 83.25% of the companies in the same industry.
- With a decent Return On Invested Capital value of 1.58%, LGND is doing good in the industry, outperforming 78.53% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for LGND is significantly below the industry average of 12.65%.
- The 3 year average ROIC (1.12%) for LGND is below the current ROIC(1.58%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROIC | 1.58% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
1.3 Margins
- The Profit Margin of LGND (19.34%) is better than 90.58% of its industry peers.
- LGND has a Operating Margin of 11.48%. This is amongst the best in the industry. LGND outperforms 84.29% of its industry peers.
- In the last couple of years the Operating Margin of LGND has declined.
- LGND's Gross Margin of 94.27% is amongst the best of the industry. LGND outperforms 96.34% of its industry peers.
- LGND's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% |
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
- LGND has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for LGND has been increased compared to 1 year ago.
- LGND has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for LGND is higher compared to a year ago.
2.2 Solvency
- LGND has an Altman-Z score of 5.64. This indicates that LGND is financially healthy and has little risk of bankruptcy at the moment.
- LGND has a better Altman-Z score (5.64) than 75.92% of its industry peers.
- The Debt to FCF ratio of LGND is 14.48, which is on the high side as it means it would take LGND, 14.48 years of fcf income to pay off all of its debts.
- LGND's Debt to FCF ratio of 14.48 is fine compared to the rest of the industry. LGND outperforms 77.49% of its industry peers.
- A Debt/Equity ratio of 0.47 indicates that LGND is not too dependend on debt financing.
- The Debt to Equity ratio of LGND (0.47) is worse than 61.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Altman-Z | 5.64 |
ROIC/WACC0.17
WACC9.42%
2.3 Liquidity
- LGND has a Current Ratio of 24.69. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
- LGND has a Current ratio of 24.69. This is amongst the best in the industry. LGND outperforms 93.72% of its industry peers.
- A Quick Ratio of 24.30 indicates that LGND has no problem at all paying its short term obligations.
- LGND has a better Quick ratio (24.30) than 92.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 |
3. Growth
3.1 Past
- LGND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.26%, which is quite impressive.
- Measured over the past years, LGND shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.44% on average per year.
- Looking at the last year, LGND shows a very strong growth in Revenue. The Revenue has grown by 64.83%.
- LGND shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.80% yearly.
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
3.2 Future
- LGND is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.28% yearly.
- Based on estimates for the next years, LGND will show a very strong growth in Revenue. The Revenue will grow by 20.13% on average per year.
EPS Next Y35.4%
EPS Next 2Y21.72%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue Next Year48.19%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 26.12, LGND can be considered very expensive at the moment.
- Based on the Price/Earnings ratio, LGND is valued a bit cheaper than the industry average as 79.06% of the companies are valued more expensively.
- When comparing the Price/Earnings ratio of LGND to the average of the S&P500 Index (27.93), we can say LGND is valued inline with the index average.
- With a Price/Forward Earnings ratio of 22.51, LGND is valued on the expensive side.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 77.49% of the companies listed in the same industry.
- LGND's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.77.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.12 | ||
| Fwd PE | 22.51 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, LGND is valued a bit cheaper than 78.01% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 74.87% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 121.84 | ||
| EV/EBITDA | 47.65 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of LGND may justify a higher PE ratio.
- LGND's earnings are expected to grow with 19.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.74
PEG (5Y)1.94
EPS Next 2Y21.72%
EPS Next 3Y19.77%
5. Dividend
5.1 Amount
- LGND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
190.44
-1.25 (-0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners106.73%
Inst Owner Change-0.33%
Ins Owners1.62%
Ins Owner Change-1.3%
Market Cap3.75B
Revenue(TTM)251.23M
Net Income(TTM)48.58M
Analysts85.71
Price Target248.31 (30.39%)
Short Float %6.59%
Short Ratio5.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.83%
Min EPS beat(2)10.36%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)19.98%
Min EPS beat(4)4.63%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)37.45%
EPS beat(12)12
Avg EPS beat(12)53.58%
EPS beat(16)15
Avg EPS beat(16)61.91%
Revenue beat(2)2
Avg Revenue beat(2)25.66%
Min Revenue beat(2)6.44%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)18.43%
Min Revenue beat(4)6.44%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.31%
Revenue beat(12)11
Avg Revenue beat(12)12.65%
Revenue beat(16)14
Avg Revenue beat(16)16.25%
PT rev (1m)0%
PT rev (3m)32.94%
EPS NQ rev (1m)0.32%
EPS NQ rev (3m)-10.34%
EPS NY rev (1m)3.65%
EPS NY rev (3m)10.42%
Revenue NQ rev (1m)0.65%
Revenue NQ rev (3m)-5.97%
Revenue NY rev (1m)-3.37%
Revenue NY rev (3m)12.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.12 | ||
| Fwd PE | 22.51 | ||
| P/S | 14.92 | ||
| P/FCF | 121.84 | ||
| P/OCF | 117.43 | ||
| P/B | 3.94 | ||
| P/tB | 9.17 | ||
| EV/EBITDA | 47.65 |
EPS(TTM)7.29
EY3.83%
EPS(NY)8.46
Fwd EY4.44%
FCF(TTM)1.56
FCFY0.82%
OCF(TTM)1.62
OCFY0.85%
SpS12.77
BVpS48.28
TBVpS20.77
PEG (NY)0.74
PEG (5Y)1.94
Graham Number88.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROCE | 1.99% | ||
| ROIC | 1.58% | ||
| ROICexc | 2.92% | ||
| ROICexgc | 9.48% | ||
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% | ||
| FCFM | 12.24% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
ROICexc(3y)1.91%
ROICexc(5y)2.67%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.87%
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Debt/EBITDA | 7.07 | ||
| Cap/Depr | 3.38% | ||
| Cap/Sales | 0.46% | ||
| Interest Coverage | 96.15 | ||
| Cash Conversion | 50.63% | ||
| Profit Quality | 63.32% | ||
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 | ||
| Altman-Z | 5.64 |
F-Score5
WACC9.42%
ROIC/WACC0.17
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
EPS Next Y35.4%
EPS Next 2Y21.72%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
Revenue Next Year48.19%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%
EBIT growth 1Y64.02%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year674.52%
EBIT Next 3Y155.59%
EBIT Next 5Y79.19%
FCF growth 1Y-61.26%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-66.41%
OCF growth 3Y7.19%
OCF growth 5YN/A
LIGAND PHARMACEUTICALS / LGND FAQ
What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a fundamental rating of 6 / 10 to LGND.
What is the valuation status of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a valuation rating of 5 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.
How profitable is LIGAND PHARMACEUTICALS (LGND) stock?
LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 7 / 10.
What is the financial health of LIGAND PHARMACEUTICALS (LGND) stock?
The financial health rating of LIGAND PHARMACEUTICALS (LGND) is 6 / 10.